Search results for "digoxin"

showing 10 items of 23 documents

Insulin resistance and endogenous digoxin-like factor in obese hypertensive patients with glucose intolerance

1992

Hypertensive obese subjects with glucose intolerance have hyperinsulinaemia, insulin resistance and intracellular cation imbalance resulting in increased sodium content. The aim of our study was to assess in these patients plasma levels of endogenous digoxin-like factor (EDLF), an inhibitor of the sodium-pump mechanism. We studied 14 hypertensive and 12 normotensive subjects with obesity and glucose intolerance for fasting blood glucose, and plasma insulin, C-peptide and EDLF levels: the two groups were matched for age and BMI and were studied after a 2-week wash-out period from hypotensive drugs. Compared with normotensives, hypertensive subjects had higher plasma insulin levels, a greater…

Blood GlucoseMaleDigoxinmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentEndogenyEndogenous digoxin-like factorEndocrinologyInsulin resistanceInternal medicineDiabetes mellitusInternal MedicineHumansInsulinMedicineObesityImmunoreactive insulinC-Peptidebusiness.industryInsulinBlood ProteinsGeneral MedicineGlucose Tolerance TestMiddle AgedSaponinsmedicine.diseaseObesityCardenolidesEndocrinologyHyperglycemiaHypertensionFemaleInsulin ResistanceSodium-Potassium-Exchanging ATPasebusinessIntracellularActa Diabetologica
researchProduct

Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death

2012

Some successful chemotherapeutics, notably anthracyclines and oxaliplatin, induce a type of cell stress and death that is immunogenic, hence converting the patient's dying cancer cells into a vaccine that stimulates antitumor immune responses. By means of a fluorescence microscopy platform that allows for the automated detection of the biochemical hallmarks of such a peculiar cell death modality, we identified cardiac glycosides (CGs) as exceptionally efficient inducers of immunogenic cell death, an effect that was associated with the in- hibition of the plasma membrane Na + - and K + -dependent adenosine triphosphatase (Na + /K + -ATPase). CGs ex- acerbated the antineoplastic effects of DN…

Programmed cell deathDigoxinOrganoplatinum Compoundsmedicine.medical_treatment[SDV]Life Sciences [q-bio]Antineoplastic AgentsBiosensing TechniquesBiologyPharmacologyCardiac Glycosides03 medical and health sciencesMice0302 clinical medicineImmune systemCell Line TumorNeoplasmsmedicineAnimalsHumansAnthracyclinesComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesChemotherapyGeneral Medicinemedicine.disease3. Good healthOxaliplatinOxaliplatinCell culture030220 oncology & carcinogenesisHepatocellular carcinomaCancer cellImmunogenic cell deathmedicine.drug
researchProduct

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct

Digoxin-related leukocytoclastic vasculitis in a very elderly woman: A case report

2016

International audience; Even though digoxin causes many side effects, few cases of skin involvement are recorded in the French Pharmacovigilance Database. We report a case of leukocytoclastic vasculitis (LV) very probably due to digoxin. A 91-year-old woman, hospitalized following a fall, presented cardiac decompensation in a context of rapid atrial fibrillation requiring treatment with digoxin. Eight days later, a rash appeared on her back and trunk. It was neither itchy, nor painful and persisted despite local treatment. There were no other clinical anomalies. After a few days, the rash spread with appearance of bullous lesions, ulcerations and a necrosis on lymphedema of the two legs. Am…

medicine.medical_specialtyDigoxinDigoxinContext (language use)Vascularite leucocytoclasique030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePharmacovigilanceBiopsypolycyclic compoundsmedicinecardiovascular diseasesAdverse side effects030203 arthritis & rheumatologymedicine.diagnostic_testbusiness.industryAtrial fibrillationLeukocytoclastic vasculitismedicine.diseaseEffets indésirablesDermatologyRashLymphedemaSkin biopsyDigoxinemedicine.symptomCardiology and Cardiovascular Medicinebusiness[ SDV.MHEP.DERM ] Life Sciences [q-bio]/Human health and pathology/Dermatologymedicine.drug
researchProduct

Influence of digoxin on sinus node function after pharmacologic autonomic blockade.

1983

The effect of iv digoxin on normal sinus node function was studied after pharmacologic autonomic blockade (AB) in ten patients. Sinus cycle length (SCL), sinus node recovery time (SNRT) and sinoatrial conduction time (SACT) were determined before and after AB with propranolol (0.2 mg/kg body weight) and atropine sulfate (0.04 mg/kg body weight) iv, and 15 min, 30 min, and 45 min after 1 mg iv digoxin. AB resulted in a significant decrease (P less than 0.01) in SCL (916 +/- 158 to 716 +/- 120 ms), in SNRT (1,229 +/- 221 to 871 +/- 190 ms), and in SACT (79 +/- 34 to 44 +/- 10 ms). Fifteen minutes after iv digoxin there was no significant change observed in SCL (716 +/- 120 to 708 +/- 92 ms), …

AdultAtropineMaleDigoxinDigoxinPropranololTherapeutic indexDrug DiscoveryAutonomic blockademedicineAtropine sulfateHumansCycle lengthGenetics (clinical)AgedSinoatrial NodeChemistryGeneral MedicineMiddle AgedPropranololSinus node functionAnesthesiaMolecular MedicineFemalemedicine.drugSinoatrial conductionKlinische Wochenschrift
researchProduct

Digoxin concentrations in serum and cantharides blister fluid: correlations with cardiac response.

1987

The relationship between the pharmacokinetics and dynamics of digoxin was investigated using a skin blistering technique that allows experimental access to tissue fluid concentrations. Eight healthy volunteers received digoxin, 1.0 mg, and placebo intravenously according to a double-blind crossover design. Drug concentrations were determined during a 72-hour period in serum, urine, and cantharides blister fluid (CBF). Digoxin levels in the hypothetic peripheral compartments were calculated from serum concentrations. Digoxin effects (total electromechanical systole [QS2c], left ventricular ejection time [LVETc], preejection period [PEPc], QTc time, heart rate, and T wave amplitude) were meas…

AdultMalemedicine.medical_specialtyDigoxinDigoxinSystoleUrineQT intervalElectrocardiographyBlisterPharmacokineticsInternal medicineHeart ratemedicineHumansPharmacology (medical)PharmacologyChemistryHeartmedicine.diseaseCrossover studySuction blisterEndocrinologyHeart failureCardiologyFemalecirculatory and respiratory physiologymedicine.drugClinical pharmacology and therapeutics
researchProduct

Induction of digoxin-like material production, and the digoxin binding in the unicellular organism Tetrahymena by digitoxin.

1998

Thin layer chromatographic, and laser-confocal microscopic analyses with a monoclonal antibody to digoxin also displaying high affinity to digoxigenin, were used to determine the presence and localization of cardioactive glycosides. Tetrahymena pyriformis was found to possess digitoxigenin-like material, but digoxin, digitoxin, digoxigenin, gitoxin and lanatoside C were not detected. Digitoxin treatment elicited the appearance of a digoxin-like material in the progeny generations. Digoxin was taken up by untreated Tetrahymena, especially strongly 24 h after digitoxin treatment. While the cardenolide was localized in vesicles of the cell body in untreated Tetrahymena, the engulfed digoxin ap…

DigoxinDigoxinDigitoxinBiologychemistry.chemical_compoundDigitoxinpolycyclic compoundsmedicineCardenolideDigoxigeninAnimalscardiovascular diseasesChromatography High Pressure Liquidchemistry.chemical_classificationBinding SitesMicroscopy ConfocalTetrahymena pyriformisdigestive oral and skin physiologyCell MembraneLanatoside CTetrahymenaDigitalis GlycosidesBiological TransportCell BiologyGeneral Medicinebiology.organism_classificationImmunohistochemistrycarbohydrates (lipids)EnzymechemistryBiochemistryTetrahymena pyriformiscirculatory and respiratory physiologymedicine.drugCell biology international
researchProduct

La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999

2002

Introduction and objective. Atrial fibrillation is the most common arrhythmia seen in clinical practice. The objective of this study was to know the frequency of atrial fibrillation and the characteristics of patients with atrial fibrillation in the Cardiotens study. Material and method. A cross-section study with systematic selection of the study sample. All 32,051 outpatients seen on the same day by 1,159 physicians specialized in primary-care (79%) and cardiology (21%) were prospectively added to a database including history of cardiac disease (heart failure, coronary disease or atrial fibrillation), blood pressure, and ongoing treatment. Results. Atrial fibrillation was present in 25% o…

medicine.medical_specialtyDigoxinCross-sectional studybusiness.industryAtrial fibrillationmedicine.diseaseBlood pressureInternal medicineHeart failureAntithromboticEpidemiologymedicineCardiologyPopulation studycardiovascular diseasesCardiology and Cardiovascular Medicinebusinessmedicine.drugRevista Española de Cardiología
researchProduct

Isoform specificity of cardiac glycosides binding to human Na+,K+-ATPase α1β1, α2β1 and α3β1

2009

Abstract Cardiac glycosides inhibit the Na + ,K + -ATPase and are used for the treatment of symptomatic heart failure and atrial fibrillation. In human heart three isoforms of Na + ,K + -ATPase are expressed: α 1 β 1 , α 2 β 1 and α 3 β 1 . It is unknown, if clinically used cardiac glycosides differ in isoform specific affinities, and if the isoforms have specific subcellular localization in human cardiac myocytes. Human Na + ,K + -ATPase isoforms α 1 β 1 , α 2 β 1 and α 3 β 1 were expressed in yeast which has no endogenous Na + ,K + -ATPase. Isoform specific affinities of digoxin, digitoxin, β-acetyldigoxin, methyldigoxin and ouabain were assessed in [³H]-ouabain binding assays in the abse…

PharmacologyGene isoformDigoxinDigitoxinATPaseBiologyOuabainBiochemistrymedicinebiology.proteinNa+/K+-ATPaseIntracellularCardiac glycosidemedicine.drugEuropean Journal of Pharmacology
researchProduct

Clinical Decision Support System To Prevent Toxicity In Patients Treated With Digoxin

2011

In this chapter, authors develop a system for prevention and detection of congestive heart failure and fibrillation. Due to its narrow therapeutic range more than 10% of the patients treated with DGX can suffer toxic effects, but it is estimated that half of the cases of digitalis toxicity could be prevented. Two multivariate models were developed to prevent digitalis toxicity.

medicine.medical_specialtyDigoxinbusiness.industryToxicityMedicineIn patientbusinessIntensive care medicineClinical decision support systemmedicine.drug
researchProduct